Allurion Technologies stock soars on clinical study announcement
Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to initiate a clinical study aimed at optimizing muscle mass during GLP-1 therapy in combination with the Allurion Program.
Allurion Technologies Inc (ALUR) Stock: A Deeper Look at Its True Potential
Allurion Technologies Inc (ALUR) stock saw a modest uptick, ending the day at $8.69 which represents a slight increase of $4.99 or 134.86% from the prior close of $3.7. The stock opened at $16.79 and touched a low of $7.
Allurion Stock Skyrockets 80% After Hours Following Clinical Study Announcement
In one research, over four months participants on the Allurion Program showed a 14% drop in overall weight and a 5.6% gain in lean body mass. Another trial revealed a 15.7% weight decrease devoid of effect on lean mass.
Allurion Technologies to initiate GLP-1 study optimizing for muscle mass
Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1
What’s Behind the 21.31% Gain in Allurion Technologies Inc (ALUR) Stock? Find Out Now!
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 29.90% of Allurion Technologies Inc (ALUR)’s shares, while financial institutions hold 21.21%.
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 agonists to improve muscle mass and overall body composition.
Hosted on MSN2d
Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
Allurion extends rally despite $7.4M stock and warrants offering
Allurion Technologies (ALUR) stock climbed 200% despite a ~7.4M stock and warrants offering announced by the company. Read ...
Allurion Shares Surge 185% Following $7.4 Million Fundraising Announcement
Shares of Allurion Technologies ( ALUR, Financials) surged 185% to $10.54 in midday trading after the company announced plans ...
Allurion Technologies Shares Are Up Today: What's Going On?
Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to conduct a clinical study evaluating the combination of its Allurion Program ...
Allurion Technologies to sell 1.24M shares at $6 in registered direct offering
Allurion Technologies (ALUR) announced that it has entered into a definitive securities purchase agreement with certain institutional investors ...
Business Wire3d
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a definitive ...
Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
Key Takeaways Allurion Technologies said it planned to test its gastric balloon with the key ingredient in popular ...